World Lymphoma Awareness Day 2022
World Lymphoma Awareness Day is recognized worldwide for educating people about cancer of the lymphatic system.
Lymphoma is a cancer of the lymphatic system, lymphatic glands, and lymphocytes. There are two main types of lymphoma: Hodgkin’s and Non-Hodgkin’s. The former type is more prevalent in younger patients and the latter in the elderly population.
Some of the predisposing factors include HIV virus, human T-cell lymphotrophic virus, and Epstein Barr virus. Moreover, persons exposed to high levels of ionizing radiation are at a higher risk of developing non-Hodgkin’s lymphoma. Hodgkin’s lymphoma can be transmitted genetically from other family members.
According to the World Health Organization statistics, the estimated age-standardized incidence per 100.000 people in 2020 of lymphoma is the highest in Australia and New Zealand, North America and Northern Europe. The mortality is the highest in North Africa and Melanesia.
This year, an estimated 8,540 people will be diagnosed with Hodgkin lymphoma and 80.470 people will be diagnosed with non-Hodgkin’s lymphoma in the United States. It is around 4.6% of all cancer cases in the country. The relative 5-year survival rate after being diagnosed with non-Hodgkin’s lymphoma is 74%. It is around 87% for Hodgkin’s lymphoma.
While standard ABVD chemotherapy remains the mainstay of treatment of Hodgkin’s lymphoma, a great progress has been made in the development of immunotherapeutic approaches for the treatment of non-Hodgkin’s lymphoma. The most important of them is antibody-based immunotherapy. Other approaches are surgery, radiation, and chemotherapy. So far, several monoclonal antibodies have been approved for the treatment of non-Hodgkin’s lymphoma, including Rituximab, Monjuvi, Keytruda, etc. that have demonstrated high market adoption rates.
There were also developed 3 antibody-drug conjugates to enhance the efficacy of antibodies. Polivy, Adcetris, and Zynlonta have been approved to manage lymphoma. Currently, more than 200 clinical trials are ongoing in the global lymphoma antibody therapeutics market.
Cromos Pharma has extensive experience in managing all aspects of clinical trials in hemato-oncology in all Phases, I, II, III, and post-market/observational studies. Oncology studies represent nearly 20% of all our work.
About Cromos Pharma
Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic indications. Our expert team, comprised of 95% MDs, has extensive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
Cromos Pharma has experience in delivering success in a wide range of trial types, from biosimilars and generics, to successfully managing trials of novel therapeutics in a wide range of clinical indications. Our team provides full-service solutions to international pharma and biotech companies in high-recruiting regions, assuring exceptional data quality. Cromos Pharma combines global expertise with in-depth experience and knowledge in the US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Türkiye to offer exceptional patient recruitment. Our team has met or reduced enrollment timelines in 95% of conducted trials.
We provide accelerated study start-up timelines in our regions of operation. Regulatory inspections by FDA and EMA and site audits attest to the highest quality of our clinical data.
Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is located in Portland, Oregon, USA and its European HQ is in Dublin, Ireland.
